Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company Deals

Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug

Fineline Cube Jun 10, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...

Company Deals

Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market

Fineline Cube Jun 10, 2025

US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...

Company Drug

FDA Approves Merck’s Enflonsia for Infant RSV Protection

Fineline Cube Jun 10, 2025

The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...

Company Drug

Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial

Fineline Cube Jun 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Company Drug

Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D

Fineline Cube Jun 10, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Company Deals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Fineline Cube Jun 10, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...

Company

Huahai Pharma Receives FDA Warning Letter After Inspection

Fineline Cube Jun 10, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning...

Company

Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress

Fineline Cube Jun 9, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) released its Q1 2025 financial report, showing a...

Company Deals

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology

Fineline Cube Jun 9, 2025

China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...

Company Deals

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine

Fineline Cube Jun 9, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd....

Company Drug

AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment

Fineline Cube Jun 9, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...

Company Drug

Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD

Fineline Cube Jun 9, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...

Company Deals

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech

Fineline Cube Jun 9, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced plans to invest RMB 150 million (USD 21...

Company Deals

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

Fineline Cube Jun 9, 2025

Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug...

Company Drug

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial

Fineline Cube Jun 9, 2025

China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...

Company Drug

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101

Fineline Cube Jun 9, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...

Company Deals

Kindstar Global Partners with Biostate AI to Advance Precision Medicine

Fineline Cube Jun 9, 2025

China-based Kindstar Global (HKG: 9960) announced the establishment of a joint venture (JV) with US-headquartered...

Company Medical Device

Genesis MedTech Wins NMPA Approval for Locally Developed Thrombus Aspiration Catheter

Fineline Cube Jun 9, 2025

Singapore-based Genesis MedTech announced that it has received marketing approval from China’s National Medical Products...

Company Deals

Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China

Fineline Cube Jun 6, 2025

China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA...

Company Drug

HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials

Fineline Cube Jun 6, 2025

Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...

Posts pagination

1 … 112 113 114 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.